Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 8Head & Neck 6Thoracic 5Sarcoma 4Gynecologic 4Breast 3Genitourinary 2Dermatologic 2CNS 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1

Conditions

Paraproteinemias 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tissue Banks × Plasma cell × Clear all
NCT01408225 2026-03-23

B-SCR-MM

Ohio State University Comprehensive Cancer Center

Recruiting
5,000 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡